The estimated impact of the CCR-5 Δ32 gene deletion on HIV disease progression varies with study design

AIDS

Volumn 12, Issue 17, 1998, Pages 2271-2274

  Eskild, Anne ^a   Jonassen, Tom Øystein ^a   Heger, Bernt ^b   Samuelsen, Sven Ove ^c   Grinde, Bjørn ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

AIDS; CCR 5 genotype; Cohort; Epidemiology; HIV; Progression; Risk factors

Indexed keywords

CHEMOKINE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE DELETION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION;

EID: 0032480994     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199817000-00007     Document Type: Article

References (18)

1. Deng H, Lui R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
2. Dragic I, Litwin V, Allaway GP, et al.: HIV-1 entry into the CD4+ cells is mediated by the chemokine receptor CC-CKR5. Nature 1996, 381:667-673.
3. Huang Y, Paxton W, Wolinsky S, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
4. Dean M, Carrington, Winkler C, et al.: Genetic restriction of HIV-1 infection and the progression to AIDS by a deletion allele of the CCR5 structural gene. Science 1996, 273:1856-1862.
5. Fugen-Olsen J, Iversen AKN, Garred P, et al.: Heterozygosity for a deletion in the CKR5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11:305-310.
6. Garred P, Eugen-Olsen J, Iversen AKN, et al.: Dual effect of CCR5 A32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group [letter]. Lancet 1997, 349:1884.
7. Smith MW, Dean M, Carrington M, Hutteley GA, O'Brien SJ: CCR5-A32 gene deletion in HIV-1 infected patients [letter]. Lancet 1997, 350:741.
8. Stewart GJ, Ashton IJ, Biti RA, et al.: Increased frequency of CCR-5 A32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 1997, 11:1833-1838.
9. Michael NL, Chang G, Louie IG, et al.: The role of viral phenotype and the CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997, 3:338-340.
10. Garred P: Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis? Lancet 1998, 351:2-3.
11. Brookmeyer R, Gail MH, Polk F: The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol 1987, 126:14-24.
12. Eskild A, Magnus P, Brekke T, et al.: The impact of exposure group on the progression rate to acquired immunodeficiency syndrome. Scand J Infect Dis 1997, 29:103-109.
13. Nilsen Ø, Hasseltvedt V, Lystad A: Number of HIV and AIDS Cases in Norway (in Norwegian). Notification System for Infectious Diseases in Norway (MSIS-Rapport). Oslo: National Institute of Public Health; 1993.
14. Central Bureau of Statistics: Causes of Death (Health Statistics). Oslo: Central Bureau of Statistics: 1995.
15. Ancelle-Park R: Expanded European AIDS case definition. Lancet 1993, 341:441.
16. Cox DE, Oakes D: Analysis of Survival Data. London: Chapman and Hall; 1984:177-178.
17. Alcabes P, Munoz A, Vlahov D, Friedland GH: Incubation period of human immunodeficiency virus. Epidemiol Rev 1993, 15:303-318.
18. Doms RW, Peiper SC: Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 1997, 235:179-190.